Accordingly, a numerical trend toward higher remission/LDA rates was observed in the RTX-originator group across disease activity indices; however, these differences did not reach statistical significance and likely reflect baseline imbalances in disease severity and prior treatment exposure.
← all excerpts
Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center.
1
—
—